About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
Please click here for clinical trial information.
FOLLOW GENMAB: Tweets by Genmab
357 articles with Genmab A/S
Genmab A/S Announces Financial Results For The First Nine Months Of 2016 And Improves 2016 Financial Guidance
Genmab A/S Announces Financial Results For The First Half Of 2016 And Improves 2016 Financial Guidance
Genmab A/S Announces Positive Topline Result In Phase III POLLUX Study Of Daratumumab In Relapsed Or Refractory Multiple Myeloma
Genmab A/S Release: CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) For Relapsed And Refractory Multiple Myeloma
Genmab A/S Announces FDA Approval Of DARZALEX (Daratumumab) For Multiple Myeloma And Updates Financial Guidance
Genmab A/S Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients
Genmab A/S Announces Completion Of Rolling Submission Of Biologics License Application For Daratumumab In Multiple Myeloma And Achievement Of A USD 15 Million Milestone
Genmab A/S Announces European Regulatory Submission For Ofatumumab As Maintenance Therapy For Relapsed CLL
Genmab A/S Announces Start Of Rolling Submission Of Biologics License Application For Daratumumab For Double Refractory Multiple Myeloma To The FDA